Hexagon Capital Partners’s Cytosorbents Corp CTSO Stock Holding History

Hexagon Capital Partners’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,333	Closed	-$3.33K	–	445
2025 Q1	$3.33K	Hold	3,333	–	–	﹤0.01%	1279
2024 Q4	$3.03K	Hold	3,333	–	–	﹤0.01%	1315
2024 Q3	$5K	Hold	3,333	–	–	﹤0.01%	1055
2024 Q2	$2.34K	Hold	3,333	–	–	﹤0.01%	1144
2024 Q1	$3.17K	Hold	3,333	–	–	﹤0.01%	1073
2023 Q4	$3.7K	Hold	3,333	–	–	﹤0.01%	1025
2023 Q3	$6.27K	Hold	3,333	–	–	﹤0.01%	860
2023 Q2	$12K	Hold	3,333	–	–	﹤0.01%	696
2023 Q1	$11.2K	Hold	3,333	–	–	﹤0.01%	702
2022 Q4	$5.17K	Hold	3,333	–	–	﹤0.01%	908
2022 Q3	$5K	Hold	3,333	–	–	﹤0.01%	918
2022 Q2	$7K	Hold	3,333	–	–	﹤0.01%	718
2022 Q1	$11K	Hold	3,333	–	–	﹤0.01%	611
2021 Q4	$14K	Hold	3,333	–	–	﹤0.01%	559
2021 Q3	$27K	Hold	3,333	–	–	0.01%	435
2021 Q2	$25K	Hold	3,333	–	–	0.01%	422
2021 Q1	$28K	Hold	3,333	–	–	0.01%	370
2020 Q4	$26K	Hold	3,333	–	–	0.01%	350
2020 Q3	$26K	Buy	+3,333	New	+$30.1K	0.01%	322

Other funds holding CTSO

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hexagon Capital Partners's CTSO Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Cytosorbents Corp (CTSO) in Q2 2025, closing a stake of 3,333 shares — an estimated $3.33K sold.

Hexagon Capital Partners first reported a position in CTSO in Q3 2020 and held it in 19 quarters. The position peaked at $28K in Q1 2021. 45 funds tracked by Wall St. Rank hold CTSO as of Q2 2025.

Hexagon Capital Partners reported no remaining Cytosorbents Corp position as of Q2 2025 after selling out during the quarter.
Hexagon Capital Partners sold 3,333 Cytosorbents Corp shares in Q2 2025, an estimated $3.33K.
Hexagon Capital Partners first reported a position in Cytosorbents Corp in Q3 2020 and held it in 19 quarters.
Hexagon Capital Partners's Cytosorbents Corp position peaked at $28K in Q1 2021.
45 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.